Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
about
The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxisElevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.Alterations of the extracellular matrix in ovarian cancer studied by Second Harmonic Generation imaging microscopy.Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migrationProtein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cellsProstate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapyModulators of the urokinase-type plasminogen activation system for cancer.Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.Gene response of human skin fibroblasts to urokinase- and tissue-type plasminogen activators.Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
P2860
Q22253459-DC25E927-CE6F-41C8-858E-1D271EDA8E1AQ33186595-A068DDA6-24E1-482B-837C-579339C4D4A1Q33540010-B261F27F-D689-411F-A358-3971890C77AFQ35219000-E9AB0C9E-1EE9-4ABB-ACD6-212B06164C90Q35879981-67DB6668-8C3A-4B10-856D-FD25721D463DQ35885514-7B519437-A407-44E8-8D34-FFB8A374E6C2Q36640228-08868490-A01C-41AF-8683-63B89CFA259CQ36997627-84C325D6-12F0-4787-827D-1B6E0250BF03Q37733590-8C230B60-71BD-483D-9E1C-CE39634354CBQ39194903-7264B495-4775-4684-AF89-6FA81AB72E7AQ40262739-F52937FE-682E-4B1F-8F71-84A0C8D36C28Q40470278-CA694FBE-1109-43DF-8527-1B209EBBFBFAQ40637642-5CDF51DC-12EF-427B-A1FD-17ECCA21F33AQ40637647-C44C373A-46DD-428D-8645-4CDB00848450Q40676271-63C754A5-E020-4463-AD25-4C1C06D80CCAQ40784517-4F0D1069-DF32-47B0-B980-189D1643326AQ40881455-389D9A15-37C4-4037-A321-8055EC858E17Q42407503-CB83627C-57A3-4F79-BFC7-FDAB37B6905AQ43594124-106E3238-0B11-463E-B7E1-BEBD6B93452CQ44151258-4161C33A-D69B-4869-8DED-549E35D543FBQ44901198-502DC538-E6BF-4260-BD15-FCEEDA869C2AQ46913912-0D0F06B2-31D7-4150-A937-4846CFDAD95BQ46963498-60CA6D24-B4DA-48EA-906E-426E4A32F1D5Q48220228-57D53456-4D27-49A7-9F09-DE9606BE2583Q51633169-BD4C6018-846A-4A4A-A9D6-A904EBF0746AQ52858895-E4B0BA9E-183C-4B29-B272-650E01E75C8D
P2860
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Urokinase induces proliferatio ...... ed for growth factor function.
@en
type
label
Urokinase induces proliferatio ...... ed for growth factor function.
@en
prefLabel
Urokinase induces proliferatio ...... ed for growth factor function.
@en
P2093
P2860
P1433
P1476
Urokinase induces proliferatio ...... ed for growth factor function.
@en
P2093
Magdolen V
Nishiguchi T
P2860
P304
P356
10.1016/S0014-5793(98)01279-4
P407
P577
1998-10-01T00:00:00Z